Cervical dysplasia: Early intervention

Alternative Medicine Review

Volumn 8, Issue 2, 2003, Pages 156-170

  Marshall, Keri ^a,b  

^a UNIVERSITY AT BUFFALO   (United States)

^b Natl Coll of Naturopathic Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 INDOLEMETHANOL; CAROTENOID; CAUSTIC AGENT; FOLIC ACID; HOMOCYSTEINE; RETINOL; VIRUS VACCINE;

CANCER MORTALITY; CANCER RISK; CLINICAL TRIAL; COST BENEFIT ANALYSIS; DIET SUPPLEMENTATION; DIETARY INTAKE; DISEASE COURSE; DRUG EFFICACY; HUMAN; NONHUMAN; NUTRITION; NUTRITIONAL DEFICIENCY; PRECANCER; REVIEW; SEXUALLY TRANSMITTED DISEASE; SIDE EFFECT; STRAIN DIFFERENCE; SYSTEMIC THERAPY; TERATOGENESIS; UTERINE CERVIX CANCER; UTERINE CERVIX DYSPLASIA; VACCINATION; WART VIRUS;

ANTIOXIDANTS; CAROTENOIDS; DIET; FEMALE; FOLIC ACID; HOMOCYSTEINE; HUMANS; INDOLES; PAPILLOMAVIRIDAE; RISK FACTORS; UTERINE CERVICAL DYSPLASIA; VIRAL VACCINES; VITAMIN A;

EID: 0038688358     PISSN: 10895159     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (104)

1. Greenlee RT, Hill-Harmon MB, Murray T, Thun M. Cancer statistics, 2001. CA Cancer J Clin 2001;51:15-36.
2. Surveillance, Epidemiology, and End Results (SEER) Program Public-Use Data (1973-1998). National Cancer Institute, Division of Cancer Control and Population Sciences, Bethesda, MD, Surveillance Research Program, Cancer Statistics Branch, 2001.
3. Franco EL. Understanding the epidemiology of genital infection with oncogenic and nononcogenic human papillomaviruses: a promising lead for primary prevention of cervical cancer. Cancer Epidemiol Biomarkers Prev 1997;6:759-761.
4. Mitchell MF, Tortolero-Luna G, Wright T, et al. Cervical human papillomavirus infection and intraepithelial neoplasia: a review. J Natl Cancer Inst Monogr 1996;21:17-25.
5. Kurman RJ, Henson DE, Herbst AL, et al. Interim guidelines for management of abnormal cervical cytology. The 1992 National Cancer Institute Workshop. JAMA 1994;271:1866-1869.
6. Landis SH, Murray T, Bolden S, Wingo P. Cancer statistics, 1998. CA Cancer J Clin 1998;48:6-29.
7. Koutsky LA, Holmes KK, Critchlow CW, et al. A cohort study of the risk of cervical intraepithelial neoplasia grade 2 or 3 in relation to papillomavirus infection. N Engl J Med 1992;327:1272-1278.
8. Schiffman MH, Bauer HM, Hoover RN, et al. Epidemiologic evidence showing that human papillomavirus infection causes most cervical intraepithelial neoplasia. J Natl Cancer Inst 1993;85:958-964.
9. Tabrizi SN, Fairley CK, Chen S, et al. Epidemiological characteristics of women with high grade CIN who do and do not have human papillomavirus. Br J Obstet Gynaecol 1999;106:252-257.
10. No authors listed. Risk of cervical dysplasia in users of oral contraceptives, intrauterine devices or depot-medroxyprogesterone acetate. The New Zealand Contraception and Health Study Group. Contraception 1994;50:431-441.
11. Ho GY, Kadish AS, Burk RD, et al. HPV 16 and cigarette smoking as risk factors for high-grade cervical intra-epithelial neoplasia. Int J Cancer 1998;78:281-285.
12. Palefsky JM, Holly EA. Molecular virology and epidemiology of human papillomavirus and cervical cancer. Cancer Epidemiol Biomarkers Prev 1995;4:415-428.
13. Munoz N, Bosch FX. Epidemiology of cervical cancer. IARC Sci Publ 1989;94:9-39.
14. deVet HC, Knipschild PG, Sturmans F. The role of sexual factors in the aetiology of cervical dysplasia. Int J Epidemiol 1993;22:798-803.
15. Chen YH, Huang LH, Chen TM. Differential effects of progestins and estrogens on long control regions of human papillomavirus types 16 and 18. Biochem Biophys Res Commun 1996;224:651-659.
16. Yuan F, Auborn K, James C. Altered growth and viral gene expression in human papillomavirus type 16-containing cancer cell lines treated with progesterone. Cancer Invest 1999;17:19-29.
17. Autier P, Coibion M, Huet F, Grivegnee AR. Transformation zone location and intraepithelial neoplasia of the cervix uteri. Br J Cancer 1996;74:488-490.
18. Auborn KJ, Woodworth C, DiPaolo JA, Bradlow HL. The interaction between HPV infection and estrogen metabolism in cervical carcinogenesis. Int J Cancer 1991;49:867-869.
19. Rando RF, Lindheim S, Hasty L, et al. Increased frequency of detection of human papillomavirus deoxyribonucleic acid in exfoliated cervical cells during pregnancy. Am J Obstet Gynecol 1989;161:50-55.
20. Condyloma acuminatum-US 1966-1981. MMWR 1983;32:306-308.
21. Syrjanen K, Hakama M, Saarikoski S, et al. Prevalence, incidence, and estimated life-time risk of cervical human papillomavirus infections in a nonselected Finnish female population. Sex Transm Dis 1990;17:15-19.
22. Rock CL, Michael CW, Reynolds RK, Ruffin MT. Prevention of cervix cancer. Crit Rev Oncol Hematol 2000;33:169-185.
23. Kiviat NB, Koutsky LA. Specific human papillomavirus types as the casual agents of most cervical intraepithelial neoplasia: implications for current views and treatments. J Natl Cancer Inst 1993;85:934-935.
24. Miller AB, Barclay TH, Choi NW, et al. A study of cancer, parity and age at first pregnancy. J Chron Dis 1980;33:595-605.
25. Peters RK, Thomas D, Hagen DG, et al. Risk factors for invasive cervical cancer among Latinas and non-Latinas in Los Angeles County. J Natl Cancer Inst 1986;77:1063-1077.
26. Wright VC, Riopelle MA. Age at time of first intercourse v. chronologic age as a basis for Pap smear screening. Can Med Assoc J 1982;127:127-131.
27. Arora CD, Schmidt DS, Rader AE, et al. Adolescents with ASCUS: are they a high risk group? Clin Pediatr 2001;40:133-138.
28. Herrero R, Potischman N, Brinton LA, et al. A case-control study of nutrient status and invasive cervical cancer. I. Dietary indicators. Am J Epidemiol 1991;134:1335-1346.
29. Roye CF. Pap smear screening for adolescents: rationale, technique and follow-up. J Pediatr Health Care 1993;7:199-206.
30. Massad LS, Anoina D. Colposcopic and cytologic findings among adolescents referred to two urban teaching hospitals. J Pediatr Adolesc Gynecol 1996;9:190-194.
31. deVet HC, Sturmans F, Knipschild PG. The role of cigarette smoking in the etiology of cervical dysplasia. Epidemiology 1994;5:631-633.
32. Ziegler RG. Vegetables, fruits, carotenoids and the risk of cancer. Am J Clin Nutr 1991;53:251S-259S.
33. Byers T, Perry G. Dietary carotenes, vitamin C, and vitamin E as protective antioxidants in human cancers. Annu Rev Nutr 1992;12:139-159.
34. Block G, Patterson B, Subar A. Fruit, vegetables and cancer prevention: a review of the epidemiological evidence. Nutr Cancer 1992;18:1-29.
35. Steinmetz KA, Potter JD. Vegetables, fruit, and cancer prevention: a review. J Am Diet Assoc 1996;96:1027-1039.
36. Rock CL, Moskowitz A, Huizar B, et al. High vegetable and fruit diet intervention in premenopausal women with cervical intraepithelial neoplasia. J Am Diet Assoc 2001;101:1167-1174.
37. Shannon J, Thomas DB, Ray RM, et al. Dietary risk factors for invasive and in-situ cervical carcinomas in Bangkok, Thailand. Cancer Causes Control 2002;13:691-699.
38. Sporn MB, Roberts AB. Cervical dysplasia regression induced by all-trans-retinoic acid. J Natl Cancer Inst 1994;86:476-477.
39. Nagata C, Shimizu H, Higashiiwai H, et al. Serum retinol level and risk of subsequent cervical cancer in cases with cervical dysplasia. Cancer Invest 1999;17:253-258.
40. Meyskens FL Jr, Surwit E, Moon TE, et al. Enhancement of regression of cervical intraepithelial neoplasia II (moderate dysplasia) with topically applied all-trans-retinoic acid: a randomized trial. J Natl Cancer Inst 1994;86:539-543.
41. Agarwal C, Rorke EA, Irwin JC, Eckert RL. Immortalization by human papillomavirus type 16 alters retinoid regulation of human ectocervical epithelial cell differentiation. Cancer Res 1991;51:3982-3989.
42. Bartsch D, Boye B, Baust C, et al. Retinoic acid-mediated repression of human papillomavirus 18 transcription and different ligand regulation of the retinoic acid receptor beta gene in non-tumorigenic and tumorigenic HeLa hybrid cells. EMBO J 1992;11:2283-2291.
43. Khan MA, Jenkins GR, Tolleson WH, et al. Retinoic acid inhibition of human papillomavirus type 16-mediated transformation of human keratinocytes. Cancer Res 1993;53:905-909.
44. Steinmetz KA, Potter JD. Vegetables, fruit and cancer. II. Mechanisms. Cancer Causes Control 1991;2:427-442.
45. Hennekens CH, Buring JE, Manson JE, et al. Lack of effect of long-term supplementation with beta carotene on the incidence of malignant neoplasms and cardiovascular disease. N Engl J Med 1996;344:1145-1149.
46. Albanes D, Heinonen OP, Huttunen JK, et al. Effects of alpha-tocopherol and beta-carotene supplements on cancer incidence in the Alpha-Tocopherol Beta-Carotene Cancer Prevention Study. Am J Clin Nutr 1995;62:1427S-1430S.
47. Omenn GS, Goodman GE, Thornquist MD, et al. Risk factors for lung cancer and for intervention effects in CARET, the Beta-Carotene and Retinol Efficacy Trial. J Natl Cancer Inst 1996;88:1550-1559.
48. Potischman N, Herrero R, Brinton LA, et al. A case-control study of nutrient status and invasive cervical cancer. II. Serologic indicators. Am J Epidemiol 1991;134:1347-1355.
49. Nagata C, Shimizu H, Yoshikawa H, et al. Serum carotenoids and vitamins and risk of cervical dysplasia from a case-control study in Japan. Br J Cancer 1999;81:1234-1237.
50. Peng YM, Peng YS, Childers JM, et al. Concentrations of carotenoids, tocopherols, and retinol in paired plasma and cervical tissue of patients with cervical cancer, precancer, and non- cancerous diseases. Cancer Epidemiol Biomarkers Prev 1998;7:347-350.
51. VanEenwyk J, Davis FG, Bowen PE. Dietary and serum carotenoids and cervical intraepithelial neoplasia. Int J Cancer 1991;48:34-38.
52. Schiff M, Becker TM, Masuk M, et al. Risk factors for cervical intraepithelial neoplasia in Southwestern American Indian women. Am J Epidemiol 2000;152:716-726.
53. Palan PR, Mikhail MS, Goldberg GL, et al. Plasma levels of beta-carotene, lycopene, canthaxanthin, retinol, and alpha- and tautocopherol in cervical intraepithelial neoplasia and cancer. Clin Cancer Res 1996;2:181-185.
54. Romney SL, Ho GY, Palan PR, et al. Effects of beta-carotene and other factors on outcome of cervical dysplasia and human papillomavirus infection. Gynecol Oncol 1997;65:483-492.
55. Keefe KA, Schell MJ, Brewer C, et al. A randomized, double blind, Phase III trial using oral beta-carotene supplementation for women with high-grade cervical intraepithelial neoplasia. Cancer Epidemiol Biomarkers Prev 2001;10:1029-1035.
56. Mackerras D, Irwig L, Simpson JM, et al. Randomized double-blind trial of beta-carotene and vitamin C in women with minor cervical abnormalities. Br J Cancer 1999;79:1448-1453.
57. de Vet HC, Knipschild PG, Willebrand D, et al. The effect of beta-carotene on the regression and progression of cervical dysplasia: a clinical experiment. J Clin Epidemiol 1991;44:273-283.
58. Grubbs CJ, Steele VE, Casebolt T, et al. Chemoprevention of chemically-induced mammary carcinogenesis by indole-3-carbinol. Anticancer Res 1995;15:709-716.
59. Grose KR, Bjeldanes LF. Oligomerization of indole-3-carbinol in aqueous acid. Chem Res Toxicol 1992;5:188-193.
60. Stresser DM, Williams DE, Griffen DA, Bailey GS. Mechanisms of tumor modulation by indole-3-carbinol. Disposition and excretion in male Fischer 344 rats. Drug Metab Dispos 1995;23:966-975.
61. Telang NT, Suto A, Wong GY, et al. Induction by estrogen metabolite 16 alpha-hydroxyestrone of genotoxic damage and aberrant proliferation in mouse mammary epithelial cells. J Natl Cancer Inst 1992;84:634-638.
62. Stoewsand GS, Anderson JL, Munson L. Protective effect of dietary brussels sprouts against mammary carcinogenesis in Sprague-Dawley rats. Cancer Lett 1988;39:199-207.
63. Zeligs MA. Diet and estrogen status: the cruciferous connection. J Med Food 1998;1:67-81.
64. Auborn KJ, Woodworth C, DiPaolo JA, Bradlow HL. The interaction between HPV infection and estrogen metabolism in cervical carcinogenesis. Int J Cancer 1991;49:867-869.
65. Chen I, McDougal A, Wang F, Safe S. Aryl hydrocarbon receptor-mediated antiestrogenic and antitumorigenic activity of diindolylmethane. Carcinogenesis 1998;19:1631-1639.
66. Schneider J, Huh MM, Bradlow HL, Fishman J. Antiestrogen action of 2-hydroxyestrone on MCF-7 human breast cancer cells. J Biol Chem 1984;259:4840-4845.
67. Suto A, Bradlow HL, Wong GY, et al. Experimental down-regulation of intermediate biomarkers of carcinogenesis in mouse mammary epithelial cells. Breast Cancer Res Treat 1993;27:193-202.
68. Newfield L, Goldsmith A, Bradlow HL, Auborn K. Estrogen metabolism and human papillomavirus-induced tumors of the larynx: chemo-prophylaxis with indole-3-carbinol. Anticancer Res 1993;13:337-341.
69. Niwa T, Swaneck G, Bradlow HL. Alterations in estradiol metabolism in MCF-7 cells induced by treatment with indole-3-carbinol and related compounds. Steroids 1994;59:523-527.
70. Bradlow HL, Sepkovic DW, Telang NT, Osborne MP. Indole-3-carbinol. A novel approach to breast cancer prevention. Ann N Y Acad Sci 1995;768:180-200.
71. Bell MC, Crowley-Nowick P, Bradlow HL, et al. Placebo-controlled trial of indole-3-carbinol in the treatment of CIN. Gynecol Oncol 2000;78:123-129.
72. Chen DZ, Qi M, Auborn KJ, Carter TH. Indole-3-carbinol and diindolylmethane induce apoptosis of human cervical cancer cells and in murine HPV 16-transgenic preneoplastic cervical epithelium. J Nutr 2001;131:3294-3302.
73. Crews MG, Taper LJ, Ritchey SJ. Effects of oral contraceptive agents on copper and zinc balance in young women. Am J Clin Nutr 1980;33:1940-1945.
74. Butterworth CE Jr, Hatch KD, Macaluso M, et al. Folate deficiency and cervical dysplasia. JAMA 1992;267:528-533.
75. Butterworth CE Jr. Folic acid deficiency and cervical dysplasia: a potential preventable cancer risk. In: Bray G, ed. Vitamins and Cancer Prevention. Baton Rouge, LA: LSU Press; 1992.
76. Whitehead N, Reyner F, Lindenbaum J. Megaloblastic changes in the cervical epithelium: association with oral contraceptive therapy and reversal with folic acid. J Am Med Assoc 1973;226:1421-1424.
77. Butterworth CE Jr. Effect of folate on cervical cancer. Synergism among risk factors. Ann N Y Acad Sci 1992;669:293-299.
78. van Duin M, Snijders PJ, Vossen MT, et al. Analysis of human papillomavirus type 16 E6 variants in relation to p53 codon 72 polymorphism genotypes in cervical carcinogenesis. J Gen Virol 2000;81:317-325.
79. Reidy JA, Chen AT. Folic acid and chromosome breakage. II. A methionine effect similar to that in fragile X expression. Hum Genet 1984;68:189-190.
80. Herbert V. The role of vitamin B12 and folate in carcinogenesis. Adv Exp Med Biol 1986;206:293-311.
81. Childers JM, Chu J, Voigt LF, et al. Chemoprevention of cervical cancer with folic acid: a phase III Southwest Oncology Group Intergroup study. Cancer Epidemiol Biomarkers Prev 1995;4:155-159.
82. Adams RL. DNA methylation. The effect of minor bases on DNA-protein interactions. Biochem J 1990;265:309-320.
83. Hseih LL, Wainfan E, Hoshina S, et al. Altered expression of retrovirus-like sequences and cellular oncogenes in mice fed methyl-deficient diets. Cancer Res 1989;49:3795-3799.
84. Kim YI, Giuliano A, Hatch KD, et al. Global DNA hypomethylation increases progressively in cervical dysplasia and carcinoma. Cancer 1994;74:893-899.
85. Rosl F, Arab A, Klevenz B, zur Hausen H. The effect of DNA methylation on gene regulation of human papillomaviruses. J Gen Virol 1993;74:791-801.
86. Butterworth CE Jr, Hatch KD, Soong SJ, et al. Oral folic acid supplementation for cervical dysplasia: a clinical intervention trial. Am J Obstet Gynecol 1992;166;803-809.
87. Yeo AS, Schiff MA, Montoya G, et al. Serum micronutrients and cervical dysplasia in Southwestern American Indian women. Nutr Cancer 2000;38:141-150.
88. Palan PR, Mikhail MS, Basu J, Romney SL. Plasma levels of antioxidant beta-carotene and alpha-tocopherol in uterine cervix dysplasias and cancer. Nutr Cancer 1991;15:13-20.
89. Mikhail MS, Palan PR, Romney SL. Coenzyme Q0 and alpha tocopherol concentrations in cervical intraepithelial neoplasia and cervix cancer. Obstet Gynecol 2001;97:3S.
90. Basu J, Vermund SH, Mikhail M, et al. Plasma reduced and total ascorbic acid in healthy women: effects of smoking and oral contraception. Contraception 1989;39:85-93.
91. th International Symposium on Prevention & Detection of Cancer. Nice, France: April 9-15, 1989.
92. Basu J, Mikhail MS, Goldberg GL, et al. Measurements of ascorbic acid and glutathione in exfoliated cervicovaginal epithelial cells of smokers and women with cervical dysplasias. Gynecol Obstet Invest 1990;30:48-51.
93. Sundstrom H, Yrjanheikki E, Kauppila A. Low serum selenium concentration in patients with cervical or endometrial cancer. Int J Gynaecol Obstet 1984;22:35-40.
94. Thompson FE, Patterson BH, Weinstein SJ, et al. Serum selenium and the risk of cervical cancer among women in the United States. Cancer Causes Control 2002;13:517-526.
95. Mohs FE. Chemosurgery: microscopically controlled method of cancer excision. Arch Surg 1941;42:279-295.
96. Swanson NA. Mohs surgery. Technique, indications, applications, and the future. Arch Dermatol 1983;119:761-773.
97. Hudson TS. Consecutive case study research of carcinoma in situ of cervix employing local escharotic treatment combined with nutritional therapy. J Naturopathic Med 1991;2:6-10.
98. Hudson TS. Escharotic treatment for cervical dysplasia and carcinoma. J Naturopathic Med 1993;4:23.
99. Crum CP. The beginning of the end for cervical cancer? N Engl J Med 2002;347:1703-1705.
100. Borysiewicz LK, Fiander A, Nimako M, et al. A recombinant vaccinia virus encoding human papillomavirus types 16 and 18, E6 and E7 proteins as immunotherapy for cervical cancer. Lancet 1996;347:1523-1527.
101. Donnelly JJ, Martinez D, Jansen KU, et al. Protection against papillomavirus with a polynucleotide vaccine. J Infect Dis 1996;173:314-320.
102. Koutsky LA, Ault KA, Wheeler CM, et al. A controlled trial of a human papillomavirus type 16 vaccine. N Engl J Med 2002;347:1645-1651.
103. Kaunitz AM. An HPV vaccine - at last. Journal Watch Women's Health 2003;108:1-2.
104. Giuliano AR, Gapstur S. Can cervical dysplasia and cancer be prevented with nutrients? Nutr Rev 1998;56:9-16.